Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20093 in mCRPC and Advanced Solid Tumors
NCT06001255Phase 2Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jan 2024
- Primary completion
- Dec 2024
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of risvutatug rezetecan in metastatic castration-resistant prostate cancer (mCRPC) and solid tumor (advanced stage), sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Objective Response Rate up to 24 months. Started Jan 2024; status: recruiting.
02
Drugs
risvutatug rezetecan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06001255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06001255.